Aerie Pharmaceuticals’ (AERI) Buy Rating Reiterated at Mizuho

Aerie Pharmaceuticals (NASDAQ:AERI)‘s stock had its “buy” rating reissued by analysts at Mizuho in a research report issued to clients and investors on Thursday, AnalystRatings.com reports. They currently have a $54.00 price target on the stock. Mizuho’s price target points to a potential upside of 126.70% from the company’s previous close.

Several other analysts have also recently weighed in on AERI. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $62.00 price objective (down from $85.00) on shares of Aerie Pharmaceuticals in a research report on Thursday, August 8th. JMP Securities cut their price objective on Aerie Pharmaceuticals from $58.00 to $52.00 and set a “market outperform” rating on the stock in a research report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Thursday, October 24th. Piper Jaffray Companies reaffirmed a “buy” rating on shares of Aerie Pharmaceuticals in a research report on Tuesday, October 15th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $54.00 price objective on shares of Aerie Pharmaceuticals in a research report on Friday, October 25th. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Buy” and a consensus price target of $53.82.

NASDAQ AERI opened at $23.82 on Thursday. The company has a debt-to-equity ratio of 0.08, a current ratio of 2.52 and a quick ratio of 2.35. The stock has a market capitalization of $1.10 billion, a PE ratio of -5.12 and a beta of 0.51. Aerie Pharmaceuticals has a 1 year low of $17.51 and a 1 year high of $56.00. The business’s 50-day moving average is $21.18 and its 200 day moving average is $27.58.

Aerie Pharmaceuticals (NASDAQ:AERI) last posted its earnings results on Wednesday, August 7th. The company reported ($0.80) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.87) by $0.07. The company had revenue of $15.84 million for the quarter, compared to analysts’ expectations of $14.60 million. Aerie Pharmaceuticals had a negative return on equity of 89.52% and a negative net margin of 478.81%. As a group, equities research analysts anticipate that Aerie Pharmaceuticals will post -3.61 earnings per share for the current year.

In other Aerie Pharmaceuticals news, major shareholder Foresite Capital Management Ii bought 189,555 shares of the stock in a transaction dated Monday, August 12th. The stock was purchased at an average cost of $24.43 per share, for a total transaction of $4,630,828.65. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Vicente Anido, Jr. bought 26,250 shares of the stock in a transaction dated Monday, September 9th. The shares were acquired at an average price of $19.01 per share, with a total value of $499,012.50. Following the completion of the acquisition, the chief executive officer now directly owns 195,631 shares of the company’s stock, valued at approximately $3,718,945.31. The disclosure for this purchase can be found here. Over the last ninety days, insiders have acquired 562,698 shares of company stock worth $13,088,866. Insiders own 8.71% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in AERI. BlackRock Inc. lifted its holdings in shares of Aerie Pharmaceuticals by 11.0% during the second quarter. BlackRock Inc. now owns 3,358,901 shares of the company’s stock valued at $99,255,000 after purchasing an additional 331,884 shares during the last quarter. C WorldWide Group Holding A S lifted its holdings in shares of Aerie Pharmaceuticals by 235.0% during the second quarter. C WorldWide Group Holding A S now owns 456,142 shares of the company’s stock valued at $13,479,000 after purchasing an additional 320,000 shares during the last quarter. Waddell & Reed Financial Inc. lifted its holdings in shares of Aerie Pharmaceuticals by 14.8% during the second quarter. Waddell & Reed Financial Inc. now owns 1,737,627 shares of the company’s stock valued at $51,347,000 after purchasing an additional 224,655 shares during the last quarter. Bamco Inc. NY lifted its holdings in shares of Aerie Pharmaceuticals by 400.7% during the second quarter. Bamco Inc. NY now owns 275,226 shares of the company’s stock valued at $8,133,000 after purchasing an additional 220,263 shares during the last quarter. Finally, Rhenman & Partners Asset Management AB lifted its holdings in shares of Aerie Pharmaceuticals by 82.7% during the third quarter. Rhenman & Partners Asset Management AB now owns 475,000 shares of the company’s stock valued at $9,130,000 after purchasing an additional 215,000 shares during the last quarter.

About Aerie Pharmaceuticals

Aerie Pharmaceuticals, Inc, an ophthalmic pharmaceutical company, focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma, retinal diseases, and other eye diseases. Its lead product is Rhopressa, a once-daily eye drop to reduce elevated intraocular pressure (IOP) in patients with glaucoma or ocular hypertension.

Further Reading: How to calculate compound interest

Analyst Recommendations for Aerie Pharmaceuticals (NASDAQ:AERI)

Receive News & Ratings for Aerie Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aerie Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.